Clinical CDMO Neobiosis operates as a privately owned, clinical stage CDMO with two production facilities and an R&D lab, presenting opportunities for contract manufacturing, process development, and clinical trial support for biotech partners seeking GMP-compliant manufacturing and early-stage product validation.

Perinatal Assets The company focuses on isolating tissues, cells and extracellular vesicles from donated perinatal tissues, suggesting sales opportunities with biotech firms pursuing regenerative medicine, anti-aging therapies, and extracellular vesicle based products that require specialized sourcing and characterization capabilities.

Early Growth Revenue With revenue in the mid tens of millions and a modest employee base, Neobiosis appears nimble yet capable of scaling collaborations, offering potential partners clear pathways for joint development programs, tech transfer, and accelerated timelines for clinical trial manufacturing.

Innovation Pipeline An in-house IP and biologics development focus indicates opportunities for license deals, collaboration on proprietary materials, and co-development arrangements with larger players looking to augment their regenerative medicine portfolios with novel cellular or EV-based products.

Strategic Proximity Located in Gainesville/Alachua with ties to a biotechnology institute, Neobiosis is positioned to engage with regional academic partners and biopharma ecosystems for sponsored research, pilot runs, and access to a network of potential clients seeking trusted CDMO partners for early-phase programs.